Antileukocyte adhesion therapy
preclinical trials and combination therapy
Citation Manager Formats
Make Comment
See Comments
![Loading Loading](https://n.neurology.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Leukocytes appear to potentiate CNS reperfusion injury by clogging the microcirculation and infiltrating into the brain, where they release free radicals and other substances toxic to neurons. The initial step in these processes is leukocyte to endothelial cell adhesion. Both the microcirculation obstruction and the brain infiltration can be decreased by the use of specific monoclonal antibodies directed against leukocyte adhesion receptors. Experimental studies have found reduced stroke damage when antibodies that bind to either the CD-18 leukocyte adhesion molecule or its endothelial cell ligand, intercellular adhesion molecule-1 (ICAM-1), are used. Here we review the components of leukocyte to endothelial adhesion, preclinical studies of antileukocyte adhesion agents, and preclinical studies investigating combining anti-adhesion therapy with thrombolytics.
Leukocyte to endothelial cell adhesion. The migration of leukocytes from the blood into the brain is a multistep process. First, primary leukocyte-endothelial interaction (rolling) occurs. This process is mediated by P-selectin and E-selectin on the surface of the endothelial cells and by L-selectin on leukocytes1 (figure 1). On activation, firm adherence of leukocytes to the endothelial lining(sticking) is subsequently mediated by a leukocyte membrane glyco-protein receptor complex, termed CD-18 or β2-integrin, and its endothelial ligand, the ICAM-1.2,3 The CD-18 integrin complex consists of three heterodimers. All three share an identical β-subunit(also frequently called CD-18) and are distinguished from each other by distinct α-subunits. The three α-subunits are termed leukocyte function antigen (LFA-1 or CD-11a, present on all leukocytes), MAC-1 (CD-11b, present mostly on PMNs and monocytes), and P150 (CD-11c, present on neutrophils and monocytes). The corresponding counter-receptors for the CD-18 integrin complex are the ICAM family of adhesion molecules. Whereas ICAM-1 is widely expressed on many cells and binds to LFA-1 and MAC-1, ICAM-2 is expressed only on endothelial cells and leukocytes and is recognized only by LFA-1.4 Unlike …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Jessica Ailani and Dr. Ailna Masters-Israilov
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
The role of inflammation after acute strokeUtility of pursuing anti-adhesion molecule therapyThomas J. DeGraba et al.Neurology, September 01, 1998 -
Articles
Synthetic peptide derived from the Bordetella pertussis bacterium reduces infarct volume after transient middle cerebral artery occlusion in the ratR. L. Zhang, M. Chopp, W. X. Tang et al.Neurology, May 01, 1996 -
Articles
Cytokines and reperfusion injuryWayne M. Clark et al.Neurology, November 01, 1997 -
Articles
Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapyMark P. Bowes, Robert Rothlein, Susan C. Fagan et al.Neurology, April 01, 1995